On August 29, 2025, Transcode Therapeutics, Inc. held its Annual Meeting where stockholders approved all proposed measures, including the election of four directors and a stock plan amendment increasing shares by 166,724. A total of 312,283 shares were represented at the meeting, all resolutions received significant support.